Drug–drug interactions of protein kinase inhibitors in chronic myeloid leukaemia patients: A study using the French health insurance database

Abstract

AbstractThe introduction of protein kinase inhibitors (PKIs) for chronic myeloid leukaemia (CML) has considerably improved prognosis of the disease but has also demonstrated a great potential for drug–drug interactions. Using the French health insurance databases, we aim to investigate the frequency, identify the associated factors and describe the potential consequences of potential drug–drug interactions (pPKI‐DIs) between PKIs and concurrent medications in CML. A retrospective cohort study has been performed among patients with CML identified in the French healthcare database from 2011 to 2014. A pPKI‐DI is defined as the presence of drugs listed as ‘interacting’ on the same day as PKI dispensing (co‐dispensing) or in its coverage period (co‐medication) during the first year of follow‐up. The list of interacting drugs is based on the summary of products characteristics (SPCs) and Thesaurus of interactions. We performed specific nested case–control comparisons to investigate the association between PKI‐DI and each of the three potential outcomes (death, hospitalisation for adverse drug reactions and switch to another PKI). We included 3480 patients; 1429 (41%) had a co‐dispensing pPKI‐DI, and 2153 (62%) had a co‐medication pPKI‐DI; 50% of the pPKI‐DIs were ‘to be taken into account’, and 17% were ‘not recommended’. The PKI with the most interactions was imatinib, and additional common drug classes included statins, benzodiazepines and proton pump inhibitors. Multivariate analysis demonstrated that the use of a higher number of additional drugs, comorbidities at baseline, high number of prescribers and higher ages were potential risk factors. Nilotinib and dasatinib showed a tendency towards a higher risk of pPKI‐DI compared to imatinib. Despite the fact that some PKI‐DIs were potentially clinically relevant, we did not find any significant association with death, hospitalisation for adverse drug reactions and switching. These findings should increase awareness to help reduce the prevalence of PKI–drug interactions and thereby ensure better management of CML patients.